News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Encore Therapeutics Inc. Announces Successful Proof of Concept Study on Meloxicam Depot Injection



10/18/2011 11:15:26 AM

CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) today announced that it successfully completed a pre-clinical Proof of Concept (POC) study on ETI-511, its proprietary, extended release phospholipid gel (PG) depot formulation of the NSAID drug meloxicam (Mobecâ„¢). The company is developing ETI-511 as a long-acting local therapy for pain and inflammation. The key findings from the POC study are: (a) ETI-511 provided about 100-fold higher local tissue levels of meloxicam for at least 48 hours around the injection site compared to orally dosed meloxicam. (b) ETI-511 exhibited lower plasma meloxicam levels at all times compared to the oral dosing and (c) ETI-511 was well tolerated locally and systemically following subcutaneous injections.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES